|Bid||13.66 x 800|
|Ask||0.00 x 2200|
|Day's Range||18.73 - 19.81|
|52 Week Range||7.76 - 24.24|
|Beta (3Y Monthly)||2.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Emerging revolutionary treatments promise possible cures for diseases like hemophilia and muscular dystrophy—and opportunities for investors
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (Nasdaq: ABBV), launching a research effort to develop antibody treatments that can be delivered directly to the brain and target a protein called alpha-synuclein.
surged more than 20% on Friday after the gene therapy company announced a collaboration agreement with pharmaceutical giant AbbVie Inc. Under terms of the agreement, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential development, regulatory, and commercial milestone payments and royalties. LATEST NEWS: We just announced a new collaboration w/ @VoyagerTx focused on developing potential treatments for Parkinson's disease.
Shares of Voyager Therapeutics Inc. ran up 14.2% in premarket trade Friday, after the gene therapy company and AbbVie Inc. announced a collaboration to develop antibodies to treat Parkinson's disease. AbbVie's stock was still inactive ahead of the open. Under terms of the collaboration, Voyager will receive $65 million upfront and up to $245 million in preclinical and phase 1 option payments, as well as up to an additional $728 million in potential milestone payments and royalties. Voyager is also eligible to earn up to a total of $500 million in commercial milestones. Voyager's stock has lost 10% over the past three months, while AbbVie shares have declined 8.6% and the S&P 500 has gained 4.7%.
Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.
The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.
The company just licensed four drug programs for a cool $165 million up-front payment -- with the potential to receive $1.7 billion in future milestone payments.
Why Is Voyager Therapeutics Soaring Today?Share price movements Today, Voyager Therapeutics (VYGR) issued a press release announcing a strategic collaboration with Neurocrine Biosciences (NBIX). The partnership focuses on the development and
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 7) Allakos Inc (NASDAQ: ALLK ) BioTelemetry Inc (NASDAQ: ...
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
The direct benefit for Voyager Therapeutics Inc (NASDAQ:VYGR), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for BioMarin stock is 1.78 with a target price of $119.35, implying an upside potential of 21.1% over its closing price of $98.58 on September 12.
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with a net loss of $22.74 million in the second quarter of 2017. That translates to a net loss per share of $0.85 in the second quarter of 2018. Its net loss per share was $0.87 in the second quarter of 2017.
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -26.98% and -14.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?